David Tepper has a stellar investing track record, and here's what he owns now.
Corium Pharma Solutions, Inc. (“Corium Pharma Solutions” or “CPSI”), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies,...
9 Meters (NMTR) reports a positive top line from a phase II study of vurolenatide, being evaluated for short bowel syndrome in adults and a successful end-of-phase II meeting with the FDA.
December S&P 500 futures (ESZ22) are trending higher +1.11% this morning after three major US benchmark indices extended declines for the 5th consecutive session as investors continue to fret that higher...
RALEIGH, NC / ACCESSWIRE / July 6, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced...
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on 9 Meters Biopharma (NMTR – Research Report) and Sutro Biopharma (STRO – Research Report) with bullish...
Initial Draw of $20 Million to Support Funding Phase 3 Development of Vurolenatide in Short Bowel Syndrome
RALEIGH, NC / ACCESSWIRE / June 30, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced...
RALEIGH, NC / ACCESSWIRE / June 21, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, today announced...
RALEIGH, NC / ACCESSWIRE / June 13, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced...